Condylomata acuminata
Drug research and approvals for condylomata acuminata: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 5 studies of condylomata acuminata are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 5
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 2
- Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa GelNCT07698886 · Phase 2 · KTH Biopharma · starts Jul 16, 2026
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)NCT07234838 · Not reported · Jonathan Krygier · starts Feb 1, 2026
- To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 YearsNCT06756269 · Phase 2 · Shanghai Bovax Biotechnology Co., Ltd. · starts Jan 15, 2025
- Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV VaccineNCT05371353 · Not reported · Shanghai Bovax Biotechnology Co., Ltd. · starts May 14, 2022
- Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesNCT04422366 · Phase 3 · Shanghai Bovax Biotechnology Co., Ltd. · starts Apr 28, 2020
Approved 3
- ImiquimodToll-like receptor 7 agonist
- Podofilox
- Interferon alfa-2bInterferon alpha/beta receptor agonist
Phase 3 6
- Podophyllum resin
- Interferon gamma-1bInterferon gamma receptor agonist
- CyclophosphamideDNA inhibitor
- Hepatitis b virus hbsag surface protein antigenSurface antigen (HBsAg) vaccine antigen
- Tuberculin
- Epigalocatechin gallate
Phase 2 6
- Trichlorotellurate
- Ingenol mebutate
- OmigananCell membrane disrupting agent
- Berdazimer sodiumReleases NO, antimicrobial
- Trichloroacetic acid
- Curcumin
Phase 1 or earlier 4
- CidofovirHuman herpesvirus 1 DNA polymerase inhibitor
- Sinecatechins
- RanpirnasetRNA hydrolytic enzyme
- GS-9191
How its trials ended
92 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 76% met their primary endpoint, 0% missed it and 24% stopped early.
- Completed, result not reported4246%
- Met its primary endpoint1617%
- Ongoing1617%
- Status unknown1314%
- Stopped: sponsor or business decision22%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
- Stopped: other or unclear11%
| Jun 10, 2015 | Gardasil 9Human papillomavirus 9-valent vaccine (recombinant, adsorbed) | Merck Sharp & Dohme B.V. | EMA ↗ |
| Sep 18, 1998 | AldaraImiquimod | Viatris Healthcare Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA